Data show promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphomaFull data readout of Phase 1 study expected in Q1 2024Gamida Cell Ltd. (NASDAQ:GMDA), a cell
Switzerland’s regulatory authority has granted conditional approval for Moderna Inc’s (NASDAQ:MRNA) omicron-targeting bivalent booster vaccine for adults 18 years and older. Spikevax…